Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
NCT04969835 · View on ClinicalTrials.gov ↗
Study Summary
This is a first-in-human (FIH), Phase 1 open-label, multicentre dose escalation study investigating AVA6000 monotherapy administered intravenously in patients with locally advanced (unresectable) or metastatic solid tumours that are likely to be FAP positive. The study consists of an initial Phase 1a dose escalation portion and a subsequent Phase 1b dose expansion portion upon completion of the dose escalation portion.
Conditions Studied
Interventions
- DRUG AVA6000
Study Locations (9)
Other
- The Beatson West of Scotland Cancer Centre, NHS Greater Glasgow & Clyde — Glasgow
- St James's University Hospital, The Leeds Teaching Hospitals NHS Trust — Leeds
- The Royal Marsden, NHS Foundation Trust — London
- The Christie NHS Foundation Trust — Manchester
- The Freeman Hospital, Newcastle-upon-Tyne NHS Foundation Trust — Newcastle upon Tyne
- Weston Park Cancer Centre, Sheffield Teaching Hospitals NHS Foundation Trust — Sheffield
New York
- Memorial Sloan Kettering Cancer Center — New York
Texas
- University of Texas MD Anderson Cancer Center — Houston
Washington
- Fred Hutchinson Cancer Center — Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2021-07-16 |
| Est. Completion | 2026-08-15 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04969835
The ClinicalTrials.gov registry entry for NCT04969835 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avacta Life Sciences, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention — of which AVA6000 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04969835 reports 9 study locations spanning 4 distinct geographic areas — top geographies include Other, New York, Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04969835 about?
NCT04969835 is a clinical study titled "A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours". This is a first-in-human (FIH), Phase 1 open-label, multicentre dose escalation study investigating AVA6000 monotherapy administered intravenously in patients with locally advanced (unresectable) or metastatic solid tumours that are likely to be FAP positive. The study consists of an initial Phase 1...
What is the current status of trial NCT04969835?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 158 participants. The study started on 2021-07-16. Estimated completion is 2026-08-15.
What conditions does trial NCT04969835 study?
This clinical trial studies the following conditions: Breast Cancer, Urothelial Carcinoma, Soft Tissue Sarcoma, Ovarian Carcinoma, Salivary Gland Tumor. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04969835?
The interventions under investigation include: AVA6000 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04969835?
This trial is sponsored by Avacta Life Sciences, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04969835 being conducted?
This trial has 9 study locations across New York, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.